Key result
L-Arginine supplementation significantly lowered the incidence of preeclampsia in pregnant women at high risk for its development compared to placebo.
Why the study?
It remained to be assessed through randomized controlled trials whether L-arginine supplementation is effective in reducing the incidence of preeclampsia in pregnancies at risk.
Does L-Arginine supplementation reduce the incidence of preeclampsia in pregnant women at high risk of developing the disorder?
Systematic Review
Does L-Arginine supplementation reduce the incidence of preeclampsia in pregnant women at high risk of developing the disorder?
L-Arginine supplementation appears to be a safe and effective intervention for reducing the incidence of preeclampsia in high-risk pregnancies.
Answers are grounded in this paper and cite their sources.
Supports L-arginine in high-risk pregnancies to prevent preeclampsia; extends evidence from two RCTs.
Objectives: The objective of this study was to review data from randomized controlled trials to assess whether or not the supplementation of L-Arginine (L-Arg) is effective in reducing the incidence of preeclampsia (PE) in pregnancies at risk of developing the disorder. Methods: We aimed to systematic review randomized controlled trials, including those which compared L-Arg supplementation with placebo in pregnant women at high risk of PE development, analyzing PE incidence as the main outcome. Data were collected from MEDLINE/ Pubmed, EMBASE/ Elsevier, LILACS/ BVS and Cochrane. Results: A total of 46 papers were identified in the primary search. After analysis of eligibility, inclusion and exclusion criteria, two articles (which respected in detail all the stages of evaluation) were included in the present review. A risk of bias assessment was performed. Data analysis revealed that the incidence of PE was significantly lower in both studies, and no major adverse effects were reported. The limitations of this study were the lack of standardization between the trials analyzed and the relative low number of studies included. Conclusions: The supplementation with L-Arg appears to reduce the incidence of PE in pregnant women with high risk for its development.
No takes yet. Share an insight, caveat, or question.
Citrangulo et al. (2022) conducted a systematic review in Preeclampsia. L-Arginine (L-Arg) supplementation vs. Placebo was evaluated on Incidence of preeclampsia. L-Arginine supplementation significantly lowered the incidence of preeclampsia in pregnant women at high risk for its development compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: